Funding for this research was provided by:
Sysmex Inostics, Inc AES Program
Sysmex Inosctics, Inc AES Program
Sysmex Inostics, inc AES Program
Text and Data Mining valid from 2018-11-23
Received: 16 May 2018
Revised: 18 September 2018
Accepted: 19 September 2018
First Online: 23 November 2018
: J.G.F.: Advisory role for Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Celgene, Gilead, GSK, Janssen, Lilly, Merck Serono, MSD, Novartis, Pharmamar, Pfizer, Roche, Sanofi, and Sysmex-Inostics; J.T.: Has had advisory role activities for Bayer, Boehringer Ingelheim, Genentech/Roche, Lilly, MSD, Merck Serono, Merrimack, Novartis, Peptomyc, Sanofi, Symphogen, and Taiho; E.A.: Consultant or advisory role for Amgen, Bayer, Celgene, Merck Serono, Roche, and Sanofi; C.M.: Funding (equipment) to the Institution; Advisory role for Sysmex; E.D.R.: Consulting: Amgem, Bayer, Genomica, Servier, Merck Serono, Speaker Bureau: Servier, MSD. Research Funding: Roche, Merck Serono, Amgem, Astra Zeneca, Sysmex; A.V.: Consultant role for Sysmex Inostics; M.B.: Funding (equipment) to the Institution. The remaining authors declare no competing interests.
: All necessary data are included in the manuscript. The authors have no supplementary data to share.
: The study was approved by the Institutional Review Board at each hospital and was performed in accordance with the Declaration of Helsinki. All participants signed the informed consent form.
: This work was supported by Sysmex Inostics, Inc as well as the AES Programme [Grant Numbers PI15/00934, PT17/0015/0006]. The funders had no involvement in the writing of this manuscript but did review for medical accuracy prior to submission.